Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer von Iyer, Gopa, Balar, Arjun V, Milowsky, Matthew I, Bochner, Bernard H, Dalbagni, Guido, Donat, S Machele, Herr, Harry W, Huang, William C, Taneja, Samir S, Woods, Michael, Ostrovnaya, Irina, Al-Ahmadie, Hikmat, Arcila, Maria E, Riches, Jamie C, Meier, Andreas, Bourque, Caitlin, Shady, Maha, Won, Helen, Rose, Tracy L, Kim, William Y, Kania, Brooke E, Boyd, Mariel E, Cipolla, Catharine K, Regazzi, Ashley M, Delbeau, Daniela, McCoy, Asia S, Vargas, Hebert Alberto, Berger, Michael F, Solit, David B, Rosenberg, Jonathan E, Bajorin, Dean F

Volltext

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial von Funt, Samuel A, Lattanzi, Michael, Whiting, Karissa, Al-Ahmadie, Hikmat, Quinlan, Colleen, Teo, Min Yuen, Lee, Chung-Han, Aggen, David, Zimmerman, Danielle, McHugh, Deaglan, Apollo, Arlyn, Durdin, Trey D, Truong, Hong, Kamradt, Jeffrey, Khalil, Maged, Lash, Bradley, Ostrovnaya, Irina, McCoy, Asia S, Hettich, Grace, Regazzi, Ashley, Jihad, Marwah, Ratna, Neha, Boswell, Abigail, Francese, Kaitlyn, Yang, Yuanquan, Folefac, Edmund, Herr, Harry W, Donat, S Machele, Pietzak, Eugene, Cha, Eugene K, Donahue, Timothy F, Goh, Alvin C, Huang, William C, Bajorin, Dean F, Iyer, Gopa, Bochner, Bernard H, Balar, Arjun V, Mortazavi, Amir, Rosenberg, Jonathan E

Volltext

A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma von McPherson, Victor, Reardon, Brendan, Bhayankara, Aravind, Scott, Sasinya N., Boyd, Mariel E., Garcia‐Grossman, Ilana R., Regazzi, Ashley M., McCoy, Asia S., Kim, Philip H., Al‐Ahmadie, Hikmat, Ostrovnaya, Irina, Roth, Andrew J., Farooki, Azeez, Berger, Michael F., Rosenberg, Jonathan E., Solit, David B., Van Allen, Eliezer, Milowsky, Matthew I., Bajorin, Dean F., Iyer, Gopa

Volltext

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer von Brower, Blaine, McCoy, Asia, Ahmad, Hiba, Eitman, Cheryl, Bowman, I Alex, Rembisz, Jennifer, Milowsky, Matthew I

Volltext

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract von Sarfaty, Michal, Whiting, Karissa, Teo, Min Yuen, Lee, Chung‐Han, Peters, Vanessa, Durocher, Jennifer, Regazzi, Ashley M., McCoy, Asia S., Hettich, Grace, Jungbluth, Achim A., Al‐Ahmadie, Hikmat, Ostrovnaya, Irina, Chaim, Joshua, Bajorin, Dean F., Rosenberg, Jonathan E., Iyer, Gopa, Funt, Samuel A.

Volltext

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma von Abida, Wassim, Milowsky, Matthew I., Ostrovnaya, Irina, Gerst, Scott R., Rosenberg, Jonathan E., Voss, Martin H., Apolo, Andrea B., Regazzi, Ashley M., McCoy, Asia S., Boyd, Mariel E., Bajorin, Dean F.

Volltext

A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract von Sarfaty, Michal, Ostrovnaya, Irina, Teo, Min Yuen, Iyer, Gopa, Lee, Chung-Han, Peters, Vanessa, Durocher, Jennifer, Regazzi, Ashley Marie, McCoy, Asia S., Hettich, Grace, Al-Ahmadie, Hikmat, Chaim, Joshua, Bajorin, Dean F., Rosenberg, Jonathan E., Funt, Samuel Aaron

Volltext

Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial von Funt, Samuel Aaron, Lattanzi, Michael, Whiting, Karissa, Al-Ahmadie, Hikmat A., Quinlan, Colleen, Teo, Min Yuen, Kamradt, Jeffrey, Khalil, Maged F., Ostrovnaya, Irina, McCoy, Asia S., Hettich, Grace, Jihad, Marwah, Folefac, Edmund, Huang, William C., Bajorin, Dean F., Iyer, Gopa, Bochner, Bernard H., Balar, Arjun Vasant, Mortazavi, Amir, Rosenberg, Jonathan E.

Volltext

A Phase II Trial of Buparlisib in Patients with Platinum-Resistant Metastatic Urothelial Carcinoma von McPherson, Victor, Reardon, Brendan, Bhayankara, Aravind, Scott, Sasinya N., Boyd, Mariel E., Garcia-Grossman, Ilana R., Regazzi, Ashley M., McCoy, Asia S., Kim, Philip H., Al-Ahmadie, Hikmat, Ostrovnaya, Irina, Roth, Andrew J., Farooki, Azeez, Berger, Michael F., Rosenberg, Jonathan E., Solit, David B., Van Allen, Eliezer, Milowsky, Matthew I, Bajorin, Dean F., Iyer, Gopa

Volltext

A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC) von Funt, Samuel Aaron, Jatwani, Karan, Makris, Michelle, Regazzi, Ashley Marie, Lee, Chung-Han, Teo, Min Yuen, McHugh, Deaglan Joseph, McCoy, Asia S., Hettich, Grace, Wong, Phillip, Abu-Akeel, Moshen, Wolchok, Jedd D., Merghoub, Taha, Al-Ahmadie, Hikmat, Ostrovnaya, Irina, Chaim, Joshua, Durack, Jeremy C., Iyer, Gopa, Bajorin, Dean F., Rosenberg, Jonathan E.

Volltext

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC) von Keegan, Niamh M., Funt, Samuel Aaron, Kania, Brooke Elizabeth, Iyer, Gopa, Clement, Jessica Mary, McCoy, Asia S., Hettich, Grace, Ziv, Etay, Maher, Colleen Anne, Nair, Suresh, Panageas, Katherine, Bluth, Mark J., Wong, Phillip, Wolchok, Jedd D., Rosenberg, Jonathan E., Bajorin, Dean F., Callahan, Margaret K.

Volltext

Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC) von Callahan, Margaret K., Kania, Brooke Elizabeth, Iyer, Gopa, Clement, Jessica Mary, Funt, Samuel, McCoy, Asia S., Hettich, Grace, Ziv, Etay, Bluth, Mark J., Wong, Phillip, Wolchok, Jedd D., Bajorin, Dean F., Rosenberg, Jonathan E.

Volltext

Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer von Abida, Wassim, Milowsky, Matthew I., Ostrovnaya, Irina, Gerst, Scott R., Rosenberg, Jonathan E., Regazzi, Ashley Marie, McCoy, Asia S., Boyd, Mariel Elena, Bajorin, Dean F.

Volltext

Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC) von Iyer, Gopa, Balar, Arjun Vasant, Milowsky, Matthew I., Huang, William C., Woods, Michael, Donat, S. Machele, Herr, Harry W., Dalbagni, Guido, Bochner, Bernard H., Ostrovnaya, Irina, Al-Ahmadie, Hikmat, Rose, Tracy Lynn, Riches, Jamie Cathleen, Kania, Brooke Elizabeth, Boyd, Mariel Elena, Regazzi, Ashley Marie, McCoy, Asia S., Drier, Anthony, Rosenberg, Jonathan E., Bajorin, Dean F.

Volltext

Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients von Iyer, Gopa, Tully, Christopher Michael, Garcia-Grossman, Ilana Rebecca, Scott, Sasinya N., Boyd, Mariel Elena, McCoy, Asia S., Berger, Michael F., Al-Ahmadie, Hikmat, Solit, David B., Rosenberg, Jonathan E., Bajorin, Dean F.

Volltext

Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC) von Balar, Arjun Vasant, Iyer, Gopa, Milowsky, Matthew I., Huang, William C., Woods, Michael, Donat, S. Machele, Herr, Harry W., Dalbagni, Guido, Bochner, Bernard H., Ostrovnaya, Irina, Al-Ahmadie, Hikmat, Rose, Tracy Lynn, Riches, Jamie Cathleen, Kania, Brooke Elizabeth, Regazzi, Ashley Marie, McCoy, Asia S., Delbeau, Daniela, Rosenberg, Jonathan E., Bajorin, Dean F.

Volltext

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (N... von Dalbagni, Guido, Benfante, Nicole, Sjoberg, Daniel D., Bochner, Bernard H., Machele Donat, S., Herr, Harry W., Mc Coy, Asia S., Fahrner, Alicia J., Retinger, Caitlyn, Rosenberg, Jonathan E., Bajorin, Dean F.

Volltext

Land reform as counter-revolution von U.S. Foreign Policy and the Tenant, Farmers of Asia, McCoy, Al

Volltext